DOJ Seeks Injunction Over Misbranded Dental Products

The Department of Justice has asked a federal court to permanently stop a Nevada medical device manufacturer from making and selling dental products, on the government’s claim that those products are misbranded. Reported this month by ADA News, the filing is the kind of story that rarely reaches patients, because it concerns neither a diagnosis nor a technique but the regulatory scaffolding underneath both. That scaffolding is worth understanding. Nearly every material that enters a treatment room — the composite, the impression scanner, the whitening gel, the milling blank for a same-day crown — arrives under a legal classification that determines what may be claimed about it, and what must be proven first.

What “misbranded” means in device law

Misbranding is a term of art, and it is not a synonym for dangerous. Under the Federal Food, Drug, and Cosmetic Act, a device can be deemed misbranded when its labeling is false or misleading, when it lacks adequate directions for use, or when the manufacturer failed to submit the premarket notification the law requires before marketing. That last route matters in dentistry, where a large share of products fall into the moderate-risk category and reach market through premarket notification — the process most clinicians know by its statutory section number, 510(k) — by demonstrating substantial equivalence to a device already cleared. A product can be well made and still be misbranded if the company skipped that step or made claims outside what was cleared. It can also be misbranded because the box says something the file does not support.

A separate term, adulteration, generally covers manufacturing conditions: whether a facility follows the quality system requirements the FDA enforces through inspection. Injunction complaints often allege both. The distinction is not academic, because it tells you what the government is actually asking the court to fix — a records-and-claims problem, a production problem, or both.

Why the Justice Department brings these cases

The FDA inspects, warns and classifies recalls, but it does not sue on its own behalf. When the agency concludes that voluntary correction has failed, its referral goes to the Justice Department, whose Consumer Protection Branch files a civil action in federal district court seeking an injunction. The remedy sought is usually prospective rather than punitive: stop manufacturing and distributing until the company demonstrates compliance, retain an independent expert to audit the operation, and submit to reinspection before resuming. Many such actions resolve in a consent decree of permanent injunction, in which the defendant agrees to those conditions without conceding every allegation.

Two points deserve emphasis for readers inclined to draw conclusions quickly. A complaint is an allegation, not a finding, and the company is entitled to respond in court. And an injunction action is evidence that the enforcement pathway is functioning, not that the market is broadly unsafe. The honest framing is that these filings are infrequent, visible, and directed at the small tail of firms that did not correct after earlier contact.

What it changes inside a treatment room

For the patient, usually nothing immediate. Enforcement of this type typically halts future distribution rather than requiring removal of restorations already placed; where a product does present a safety concern, the mechanism is a recall, classified by the FDA according to the probability of serious harm, and communicated to purchasers through the supply chain. For clinicians, the practical burden falls on purchasing and inventory. A practice that discovers an affected lot is expected to quarantine it, follow the manufacturer’s or agency’s recall instructions, and document what was used and when — which is far easier in an operation that keeps lot numbers tied to individual appointments rather than to a stockroom shelf.

This is also where digital workflows earn their keep quietly. A clinic doing in-house milling for same-day full arch work handles fewer third-party shipments and can trace a material batch to a specific case in minutes. That traceability is not marketing; it is the unglamorous part of quality that becomes visible only when a letter arrives from a supplier. The same instinct — prevention through documentation and standards rather than reaction — runs through the profession’s research priorities, a theme we examined in the ADA’s recommendations to NIDCR for its next strategic plan.

Reading a product claim without a law degree

Public databases make more of this checkable than most people expect. The FDA maintains searchable records of device clearances, establishment registrations, recalls and reported adverse events, and each answers a narrow question: whether a product was cleared, for what stated use, by whom, and whether problems have been reported. A claim that a device treats a condition outside its cleared indication is a reasonable thing to ask about, politely and directly. So is a request to know which materials a laboratory or milling unit uses.

The practical takeaway is small and durable. Before a course of elective care — a veneer case, an implant, a full-mouth rehabilitation — ask the person planning it what brand and material will be used, and whether documentation of clearance is available on request. A clinician experienced in that kind of planning will answer without hesitation, because the answer is already in the chart. Silence or a change of subject is information too.